New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
06:10 EDTAKRXAkorn announces approval and launch of generic Prometrium
Akorn announced that its manufacturing and development partner, Sofgen Pharmaceuticals has received approval of its abbreviated new drug application, or ANDA, for Progesterone capsules, 100mg and 200mg. The approved ANDA is for the generic of Abbott Laboratories' Prometrium capsules indicated for the treatment of endometrial hyperplasia and secondary amenorrhea. Akorn has exclusive marketing rights to Sofgen's product in the U.S. and the Company has begun distribution. According to IMS Health, Progesterone capsules, 100mg and 200mg, had combined sales of approximately $170M in the U.S. based on annualizing the three months ended August 31. IMS Health sales figures exclude certain customary discounts and incentives.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
10:23 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:11 EDTAKRXAkorn initiated with Outperform, $50 target at William Blair
William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.
December 8, 2014
11:30 EDTAKRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use